Synonyms: example 1 [WO2016094821A2]
Compound class:
Synthetic organic
Comment: The chemical structure submitted to the WHO for INN rezivertinib, is identical to the structure of example 1 that is claimed in patent WO2016094821A2 by Beta Pharma [1]. This patent claims novel EGFR inhibitors that are active against mutated EGFRs that are found in cancers, i.e. third generation EGFR inhibitors. From Beta Pharma's declared pipeline, example 1 is likely to be BPI-7711, which is being investigated for the treatment of EGFRT790M-mutant non-small cell lung cancer. We await formal name>structure confirmation. Experimental evidence in WO2016094821A2 indicates that example 1 is orally bioavailable.
|
|
Classification | |
Compound class | Synthetic organic |
International Nonproprietary Names | |
INN number | INN |
11229 | rezivertinib |
Synonyms |
example 1 [WO2016094821A2] |
Database Links | |
GtoPdb PubChem SID | 404859075 |
PubChem CID | 118912975 |
Search Google for chemical match using the InChIKey | BPMZUKYFIDPLEA-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | BPMZUKYFIDPLEA |
Search PubMed clinical trials | rezivertinib |
Search PubMed titles | rezivertinib |
Search PubMed titles/abstracts | rezivertinib |
UniChem Compound Search for chemical match using the InChIKey | BPMZUKYFIDPLEA-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | BPMZUKYFIDPLEA-UHFFFAOYSA-N |